Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$125.69 USD
+1.36 (1.09%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $125.35 -0.34 (-0.27%) 6:28 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 381 - 400 ( 677 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of SRPT shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 19
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Glimpse of Launch Progress Coming in January as Sarepta Reports 3Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thinking About the US Launch of Exondys 51; Reiterate OUTPERFORM and Raise PT to $72
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sarepta Looks to Bolster its Leading Role in DMD - Inks Deal with Summit; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Good News Keeps Coming - Interference Case Means Sarepta Should be Able to Launch Unencumbered in the US; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Finally Gets to YES on Eteplirsen; Reiterate OUTPERFORM and Raise PT to $66
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H